第十一章 遗传药理学及临床合理用药

Click here to load reader

Upload: emmly

Post on 11-Jan-2016

223 views

Category:

Documents


4 download

DESCRIPTION

第十一章 遗传药理学及临床合理用药. 第一节 概 述. “ 伯氨喹溶血症 ” 在非洲黑人中较白种人更常见 ?. 这一不良反应与葡萄糖 -6- 磷酸脱氢酶( G-6-PD )缺乏导致对伯氨喹敏感的红细胞内谷胱甘肽浓度降低有关。. 是由于某些病人血浆胆碱酯酶灭活减慢,作用增强并延长的缘故。. 许多病人口服异烟肼发生外周 神经炎 ?. 现在可以将其归因于乙酰化酶缺陷者对诸如异烟肼、普鲁卡因胺和苯肼哒嗪等氧化性药物的不良反应。. 对肌松药琥珀胆碱的异常反应(呼吸肌麻痹甚至死亡) ?. 遗传药理学 ( Pharmacogenetics). - PowerPoint PPT Presentation

TRANSCRIPT

  • **

  • -6-G-6-PD **

  • *(Pharmacogenetics)*

  • *1957Mostusky,1959Friedrich Vogel1962Kalow1973(WHO)*

  • *P450SNPs2090Human Genome ProjectHGPHGP*

  • * *

  • *DNADNA2322(autosome)(sex chromosome)DNA(allele)*

  • *(genotype)S

    (phenotype) *

  • *, *

  • **

  • **

  • **

  • **

  • **P450(CYP450)CYP450

  • *-50P450 123CYP1CYP2 CYP3P450 *

  • Nelson1993P450P45040%CYPCYP255%CYP2DP450individualCYP2D6DalyCYP2D6CYP2D6*CYP2D6*6A **

  • **

  • * CYPlA2CYP450

    17- P4501A2 ( CYP1A2*

  • *CYPlA2157.8kb76CYPlA215CYPlA2*1FCYPlA20.67CYPlA2*

  • *CYPlA2

    CYPlA2C734A*

  • *CYP2C9CYP2C9 P4502C9 ( CYP2C9*

  • * CYP2C910CYP2C9*32.1~4.5 *

  • *P4502C19 ( CYP2C19CYP2C19 P450S-S-4-

    CYP2C1910(10q241-10q24.3)14 *

  • *CYP2C19*2 CYP2C19*3

    CYP2C19*2(25%)(13%)

    CYP2C19*38%1%*

  • *P4502D6(CYP2D6)CYP1%~2% 80 CYP2D6 4-(EM)(PM)*

  • *CYP2D6 5070(PM)CYP2D6 PM 5%~10% 1%36%( IM)CYP2D6*10 58% *

  • * CYP2D622CYP2D6*3ACYP2D6*4A*4BCYP2D6*5CYP2D6*6APMPMCYP2D6CYP2D6 *

  • *CYP3A4 CYP450CYP3A4 ()DNA P4503A4 (CYP3A4)*

  • *NAT2 N-(N-acetyltransferaseNAT)N- NAT *

  • *,

    10~30%40~70%

    *

  • *

    *

  • *N-N-acetyltransferase, NATNAT1NAT2NAT2NAT1*

  • *NAT2NAT2NAT2*49NAT2NAT2*4NAT2*4 *

  • * 30~5070~8095% *

  • **

  • **

  • **

  • *2NATlNATlNAT287NATlNAT2NAT1NATl*10NAT1NATl* 10*

  • *() ()(ADH) 4kDADH5*

  • ADH5ADHADHADHsADHsADHs

    **

  • *(ALDH) ALDHALDH7ALDHALDHlALDH2ALDHs *

  • *ALDH2ALDH

    *

  • **ALDH2

  • **

  • *-6- -6-(Glucose 6-phosphatedehydrogenaseG6PD)G6PDXG6PD(GSH) *

  • *G6PDNADPHGSH()H202GSHG6PDG6PD *

  • *TPMTTMT-OCOMT*

  • *-OCOMTO-COMT25%50%COMT22q11.1~q11.26COMT*

  • *(thlopurina methyl-transferaseTPMT)(thlopurina methyl-transferaseTPMT)6-(6-MP)TPMT 6-MP10~15 6-MP *

  • *MDRI P-P-ATP *

  • *P-MDRIC3435T P-3435CC P-AUC3435TT 3435CC55%3435TT 20%*

  • **

  • *>1%*

  • Ser49GlyGly389Arg1 Ser49GlyGly389Arg 389Arg**

  • 1 2 2 16 (Gly-16Arg) Gly16Arg165.32.3

    **

  • *(ACE)ACE ACE ACE 16 ACE I AT1RA1166C *

  • * *

  • * *

  • *77q3170508()(F508)F50870~9050 *

  • *24(cystic fibrosis transmembrane conductance regulatorCFTR)ATPCFTR3(F508)ATPCFTR*

  • *Ca2+ Ca2+Ca2+ATP*

  • *Ca2+*

  • * 198825*

  • *

    5*

  • *K KKKK

    *

  • **

    *, ;40genetic locuspedigree(nortriptyline)identical twinfraternal twinheredity coefficient,heritability

    h01010.880.98

    N-(genetic polymorphismP-450(debrisoquine)(extensive metabolizerEM)(poor metabolizer, PM)DNADNAmRNAS-N-